|
Methdilazine
drug data and news
Methdilazine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Methdilazine
|
| Brand Names/Synonyms |
Bristaline; Dilosyn; Disyncram; Disyncran; MJ 5022; Md; Methdilazine; Methdilazine Hcl; Methdilazine Hydrochloride; Methdilazine Monohydrochloride; Methdilazine [Usan:Ban:Inn]; Methdilazinum [Inn-Latin]; Methilazine Hydrochloride; Methodilazine; Metodilazina [Inn-Spanish]; NCI-C60720; Product 5022; Tacaryl; Tacaryl Hydrochloride; Tacazyl; Tacryl |
| Indication |
Used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Methdilazine is a histamine H1 antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. |
| Mechanism Of Action |
Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. |
Methdilazine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Syrup, Tablets, Chewable tablets |
| Drug_Category |
Antihistamines; ATC:R06AD04 |
| Absorption |
Well absorbed in the digestive tract. |
| Interactions |
Not Available |
| Toxicity |
Symptoms of overdose include clumsiness or unsteadiness; convulsions; drowsiness; dryness of mouth, nose, or throat ; feeling faint; flushing or redness of face; hallucinations; muscle spasms (especially of neck and back); restlessness; shortness of breath or troubled breathing; shuffling walk; tic-like movements of head and face; trembling and shaking of hands; trouble in sleeping. |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine |
| Chemical Formula |
C18H20N2S |
| Molecular Weight |
296.431 g/mol |
| Smiles String |
CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42 |
| Melting Point |
87-88 °C |
| Water Solubility |
0.348 mg/L |
| State |
Solid |
| LogP/Hphobicity |
4.781 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Methdilazine.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00713 |
| CAS Registry Number |
1982-37-2 |
| KEGG Compound ID |
C07175 |
| PubChem ID |
SID:9384 |
| PharmGKB ID |
PA450414 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
